Navigation Links
Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
Date:7/20/2009

e expressed or implied by such statements. These risks and uncertainties include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form
'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2. Wyeth Announces Holder Right to Surrender Convertible Debentures
3. Wyeth Declares Common Stock Dividend
4. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
5. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
6. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
7. Wyeth Declares Common and Preferred Stock Dividends
8. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
9. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
10. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
11. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- An entire month is dedicated to one of the ... (CMT) – a debilitating neuromuscular disease affecting the arms, ... and foot and hand deformities. CMT affects 1 in ... a progressive disease, and over time patients lose the ... as leg braces, wheelchairs and scooters to get around. ...
(Date:9/19/2014)... Barnhardt Manufacturing Company has earned ... Organic Cotton . The USDA Certified Biobased Product Label ... meets or exceeds levels set by USDA. Biobased products ... in significant part of agricultural, forestry, or marine ingredients. ... to be immediately identified as a USDA certified BioPreferred ...
(Date:9/18/2014)... September 18, 2014 Bipartisan passage this ... bill designed to stimulate development and commercialization of new ... praised by leaders of SPIE, the international society ... American Manufacturing and Innovation (RAMI) Act, now moves to ... have said they are optimistic that it will win ...
(Date:9/18/2014)... Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), ... algae bioactive compounds and metabolic processes, is pleased to announce ... of directors. Ms. Nola E. Masterson , a ... the board effective September 17, 2014. "We,re ... join our board," states Andrew Dahl , President and ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... Alternext US: NBS), which is pioneering the pre-disease collection,processing ... medical need,today announced that it has reached a major ... the first ever collection center for collection of,adult stem ... in New York,City and has chosen Bruce Yaffe, M.D., ...
... MedImmune today announced that,it has initiated a Phase ... the safety of subcutaneous dosing of a humanized monoclonal ... that inhibiting the IL-5R pathway may lead to a ... of this antibody. , ...
... 4 Azur Pharma Limited ("Azur") today,announced that ... BioSante,Pharmaceuticals, Inc ("BioSante")(Nasdaq: BPAX ) to ... drying gel formulation of estradiol which is,indicated for ... with menopause. Elestrin was approved by the U.S. ...
Cached Biology Technology:NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 4MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2
(Date:9/18/2014)... manipulate spoken language is unique to humans. "The genetic ... of human evolution to make this possible are largely ... now have," says Wolfgang Enard, Professor of Anthropology and ... the molecular biological basis of language Enard has now ... latest study, undertaken in collaboration with scientists at several ...
(Date:9/18/2014)... turned its newborn screening program into a model other states ... the first-ever Newborn Screening Quality Award from the March of ... M.P.H., Arizona,s Department of Health Services director, with the award ... policy of full transparency for the length of time it ... lab for analysis, and set a target of having 95 ...
(Date:9/18/2014)... researchers from several disciplines will be celebrated tonight at ... roles in improving the health of premature infants and ... revolutions. The researchers, whose work was supported by the ... the former Atomic Energy Commission, will be honored at ... DC. A bipartisan group of Members of Congress will ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... "where did life on Earth start?" now has a new ... correct, life would have originated between sheets of mica that ... so-called "life between the sheets" mica hypothesis was developed by ... funding from the National Science Foundation (NSF). This hypothesis was ...
... microtubules emanating from each of the spindle poles meet ... the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, ... of this overlap. In a study published today in ... anti-parallel microtubule overlaps in vitro, and identify two proteins ...
... group of scientists has identified a genetic variant that ... Jewish and other populations. The study, published by Cell ... of Human Genetics , associates a deletion on chromosome ... a psychiatric illness that affects 1% of the world ...
Cached Biology News:The secret of life may be as simple as what happens between the sheets -- mica sheets 2The secret of life may be as simple as what happens between the sheets -- mica sheets 3Constant overlap 2Large risk schizophrenia marker revealed 2
... is a new product number, created ... If showing no availability yet, please ... (Z71,487-9) or contact customer service for ... 100 mm, No. of sidearm 4 ...
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
TGase3 (S-20)...
Amodiaquine...
Biology Products: